{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-79.6","upperLimit":"-15.0","value":"-70.9"}]}],"title":"Week 5 (n=30)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-85.7","upperLimit":"-42.9","value":"-77.0"}]}],"title":"Week 9 (n=29)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-84.2","upperLimit":"-36.0","value":"-60.0"}]}],"title":"Week 13 (n=27)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-79.3","upperLimit":"-37.1","value":"-59.5"}]}],"title":"Week 17 (n=26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-80.1","upperLimit":"-19.1","value":"-64.5"}]}],"title":"Week 21 (n=24)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-76.2","upperLimit":"3.6","value":"-56.4"}]}],"title":"Week 25 (n=20)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-78.4","upperLimit":"-22.8","value":"-52.8"}]}],"title":"Week 29 (n=21)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-83.8","upperLimit":"22.0","value":"-35.0"}]}],"title":"Week 33 (n=15)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-83.4","upperLimit":"-41.4","value":"-71.1"}]}],"title":"Week 37 (n=13)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-78.1","upperLimit":"-22.4","value":"-57.3"}]}],"title":"Week 41 (n=11)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-81.8","upperLimit":"-47.5","value":"-59.1"}]}],"title":"Week 45 (n=8)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-74.0","upperLimit":"-0.9","value":"-59.0"}]}],"title":"Week 49 (n=7)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-81.5","upperLimit":"-29.3","value":"-49.0"}]}],"title":"Week 53 (N=8)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-78.4","upperLimit":"-21.9","value":"-65.1"}]}],"title":"Week 57 (n=6)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-92.5","upperLimit":"23.1","value":"-59.2"}]}],"title":"Week 61 (n=3)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-79.6","upperLimit":"33.2","value":"-69.2"}]}],"title":"Week 65 (n=3)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-88.8","upperLimit":"-13.4","value":"-64.2"}]}],"title":"Week 69 (n=4)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-47.5","upperLimit":"-47.5","value":"-47.5"}]}],"title":"Week 73 (n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-86.8","upperLimit":"-66.7","value":"-76.8"}]}],"title":"Week 77 (n=2)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-53.8","upperLimit":"27.1","value":"-13.3"}]}],"title":"Week 81 (n=2)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Urinary N-telopeptide (of type 1 collagen) corrected for urine creatinine (uNTX/Cr) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in uNTX/Cr was measured over time.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg dose on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.","id":"OG000","title":"Denosumab"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Set with available data at each time point (n).","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, and 81","title":"Percent Change From Baseline in Urinary N-telopeptide Corrected for Urine Creatinine","type":"SECONDARY","unitOfMeasure":"percent change"}